May 13, 2014
Astellas Execs at Earning Briefing Astellas Pharma said on May 12 that it saw its FY2013 group sales soar 16.1% over the previous year, underpinned by its prostate cancer agent Xtandi (enzalutamide) and overactive bladder treatment Betanis (mirabegron). Sales stood...read more